Serogrouping and seroepidemiology of North European hantaviruses using a novel broadly targeted synthetic nucleoprotein antigen array.
Identifieur interne : 000B96 ( PubMed/Curation ); précédent : 000B95; suivant : 000B97Serogrouping and seroepidemiology of North European hantaviruses using a novel broadly targeted synthetic nucleoprotein antigen array.
Auteurs : Bengt Rönnberg [Suède] ; Olli Vapalahti [Finlande] ; Marco Goeijenbier [Pays-Bas] ; Chantal Reusken [Pays-Bas] ; Ke Gustafsson [Suède] ; Jonas Blomberg [Suède] ; Ke Lundkvist [Suède]Source :
- Infection ecology & epidemiology [ 2000-8686 ] ; 2017.
Abstract
Introduction: Hantaviruses are globally distributed zoonotic pathogens. Great diversity and high antigenic cross-reactivity makes diagnosis by traditional methods cumbersome. Materials and methods: 'Megapeptides', 119-120-mers from the amino terminus of the nucleoprotein of 16 hantaviruses, representing the four major branches of the hantavirus phylogenetic tree, were utilized in a novel IgG-based hantavirus suspension multiplex immunoassay (HSMIA) for detection of past hantavirus infections in 155 North European human samples. We compared HSMIA with established EIAs and focus reduction neutralization test (FRNT). Results and discussion: The Puumala hantavirus (PUUV) component in the HSMIA gave concordant results with a PUUV IgG EIA in 142 sera from Northern Sweden (of which 31 were EIA positive, 7 borderline and 104 EIA negative, sensitivity 30/31 = 97%, specificity 104/ 104 = 100%, 134/135 = 99% concordance), with another immunoassay in 40 PUUV IgG positive sera from Finland (36/40 = 90% sensitivity), and was concordant in 8 of 11 cases with PUUV and DOBV neutralization titers, respectively. Two major IgG reactivity patterns were found: (i) a PUUV-specific pattern covering phylogroup IV and its serogroups B and C; and (ii) a Dobrava virus (DOBV)-specific pattern, covering the serogroup A portion of phylogroup III. In addition, we found several minor patterns with reactivity to only one or two megapeptides indicating additional hantaviruses infecting humans in the Swedish and Finnish populations. Conclusion: The broadly reactive and rational HSMIA yielded results highly correlated with the established PUUV EIAs and the NT results. It is a sensitive and specific assay, which will be suited for efficient serosurveillance of hantaviruses in humans. Its use in animals should be further investigated.
DOI: 10.1080/20008686.2017.1350086
PubMed: 28815001
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000B96
Links to Exploration step
pubmed:28815001Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Serogrouping and seroepidemiology of North European hantaviruses using a novel broadly targeted synthetic nucleoprotein antigen array.</title><author><name sortKey="Ronnberg, Bengt" sort="Ronnberg, Bengt" uniqKey="Ronnberg B" first="Bengt" last="Rönnberg">Bengt Rönnberg</name><affiliation wicri:level="1"><nlm:affiliation>Section of Clinical Microbiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Section of Clinical Microbiology, Department of Medical Sciences, Uppsala University, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Vapalahti, Olli" sort="Vapalahti, Olli" uniqKey="Vapalahti O" first="Olli" last="Vapalahti">Olli Vapalahti</name><affiliation wicri:level="1"><nlm:affiliation>Department of Veterinary Biosciences and Virology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Veterinary Biosciences and Virology, University of Helsinki and Helsinki University Hospital, Helsinki</wicri:regionArea></affiliation></author><author><name sortKey="Goeijenbier, Marco" sort="Goeijenbier, Marco" uniqKey="Goeijenbier M" first="Marco" last="Goeijenbier">Marco Goeijenbier</name><affiliation wicri:level="1"><nlm:affiliation>Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Viroscience, Erasmus MC, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Reusken, Chantal" sort="Reusken, Chantal" uniqKey="Reusken C" first="Chantal" last="Reusken">Chantal Reusken</name><affiliation wicri:level="1"><nlm:affiliation>Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Viroscience, Erasmus MC, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Gustafsson, Ke" sort="Gustafsson, Ke" uniqKey="Gustafsson " first=" Ke" last="Gustafsson"> Ke Gustafsson</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Clinical Microbiology, Uppsala University Hospital, Uppsala, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Laboratory of Clinical Microbiology, Uppsala University Hospital, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Blomberg, Jonas" sort="Blomberg, Jonas" uniqKey="Blomberg J" first="Jonas" last="Blomberg">Jonas Blomberg</name><affiliation wicri:level="1"><nlm:affiliation>Section of Clinical Microbiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Section of Clinical Microbiology, Department of Medical Sciences, Uppsala University, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Lundkvist, Ke" sort="Lundkvist, Ke" uniqKey="Lundkvist " first=" Ke" last="Lundkvist"> Ke Lundkvist</name><affiliation wicri:level="1"><nlm:affiliation>Section of Clinical Microbiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Section of Clinical Microbiology, Department of Medical Sciences, Uppsala University, Uppsala</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28815001</idno><idno type="pmid">28815001</idno><idno type="doi">10.1080/20008686.2017.1350086</idno><idno type="wicri:Area/PubMed/Corpus">000B96</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B96</idno><idno type="wicri:Area/PubMed/Curation">000B96</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B96</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Serogrouping and seroepidemiology of North European hantaviruses using a novel broadly targeted synthetic nucleoprotein antigen array.</title><author><name sortKey="Ronnberg, Bengt" sort="Ronnberg, Bengt" uniqKey="Ronnberg B" first="Bengt" last="Rönnberg">Bengt Rönnberg</name><affiliation wicri:level="1"><nlm:affiliation>Section of Clinical Microbiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Section of Clinical Microbiology, Department of Medical Sciences, Uppsala University, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Vapalahti, Olli" sort="Vapalahti, Olli" uniqKey="Vapalahti O" first="Olli" last="Vapalahti">Olli Vapalahti</name><affiliation wicri:level="1"><nlm:affiliation>Department of Veterinary Biosciences and Virology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Veterinary Biosciences and Virology, University of Helsinki and Helsinki University Hospital, Helsinki</wicri:regionArea></affiliation></author><author><name sortKey="Goeijenbier, Marco" sort="Goeijenbier, Marco" uniqKey="Goeijenbier M" first="Marco" last="Goeijenbier">Marco Goeijenbier</name><affiliation wicri:level="1"><nlm:affiliation>Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Viroscience, Erasmus MC, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Reusken, Chantal" sort="Reusken, Chantal" uniqKey="Reusken C" first="Chantal" last="Reusken">Chantal Reusken</name><affiliation wicri:level="1"><nlm:affiliation>Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Viroscience, Erasmus MC, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Gustafsson, Ke" sort="Gustafsson, Ke" uniqKey="Gustafsson " first=" Ke" last="Gustafsson"> Ke Gustafsson</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Clinical Microbiology, Uppsala University Hospital, Uppsala, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Laboratory of Clinical Microbiology, Uppsala University Hospital, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Blomberg, Jonas" sort="Blomberg, Jonas" uniqKey="Blomberg J" first="Jonas" last="Blomberg">Jonas Blomberg</name><affiliation wicri:level="1"><nlm:affiliation>Section of Clinical Microbiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Section of Clinical Microbiology, Department of Medical Sciences, Uppsala University, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Lundkvist, Ke" sort="Lundkvist, Ke" uniqKey="Lundkvist " first=" Ke" last="Lundkvist"> Ke Lundkvist</name><affiliation wicri:level="1"><nlm:affiliation>Section of Clinical Microbiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Section of Clinical Microbiology, Department of Medical Sciences, Uppsala University, Uppsala</wicri:regionArea></affiliation></author></analytic><series><title level="j">Infection ecology & epidemiology</title><idno type="ISSN">2000-8686</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><b>Introduction</b>: Hantaviruses are globally distributed zoonotic pathogens. Great diversity and high antigenic cross-reactivity makes diagnosis by traditional methods cumbersome. <b>Materials and methods</b>: 'Megapeptides', 119-120-mers from the amino terminus of the nucleoprotein of 16 hantaviruses, representing the four major branches of the hantavirus phylogenetic tree, were utilized in a novel IgG-based hantavirus suspension multiplex immunoassay (HSMIA) for detection of past hantavirus infections in 155 North European human samples. We compared HSMIA with established EIAs and focus reduction neutralization test (FRNT). <b>Results and discussion</b>: The Puumala hantavirus (PUUV) component in the HSMIA gave concordant results with a PUUV IgG EIA in 142 sera from Northern Sweden (of which 31 were EIA positive, 7 borderline and 104 EIA negative, sensitivity 30/31 = 97%, specificity 104/ 104 = 100%, 134/135 = 99% concordance), with another immunoassay in 40 PUUV IgG positive sera from Finland (36/40 = 90% sensitivity), and was concordant in 8 of 11 cases with PUUV and DOBV neutralization titers, respectively. Two major IgG reactivity patterns were found: (i) a PUUV-specific pattern covering phylogroup IV and its serogroups B and C; and (ii) a Dobrava virus (DOBV)-specific pattern, covering the serogroup A portion of phylogroup III. In addition, we found several minor patterns with reactivity to only one or two megapeptides indicating additional hantaviruses infecting humans in the Swedish and Finnish populations. <b>Conclusion</b>: The broadly reactive and rational HSMIA yielded results highly correlated with the established PUUV EIAs and the NT results. It is a sensitive and specific assay, which will be suited for efficient serosurveillance of hantaviruses in humans. Its use in animals should be further investigated.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">28815001</PMID><DateRevised><Year>2019</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2000-8686</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2017</Year></PubDate></JournalIssue><Title>Infection ecology & epidemiology</Title><ISOAbbreviation>Infect Ecol Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Serogrouping and seroepidemiology of North European hantaviruses using a novel broadly targeted synthetic nucleoprotein antigen array.</ArticleTitle><Pagination><MedlinePgn>1350086</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/20008686.2017.1350086</ELocationID><Abstract><AbstractText><b>Introduction</b>: Hantaviruses are globally distributed zoonotic pathogens. Great diversity and high antigenic cross-reactivity makes diagnosis by traditional methods cumbersome. <b>Materials and methods</b>: 'Megapeptides', 119-120-mers from the amino terminus of the nucleoprotein of 16 hantaviruses, representing the four major branches of the hantavirus phylogenetic tree, were utilized in a novel IgG-based hantavirus suspension multiplex immunoassay (HSMIA) for detection of past hantavirus infections in 155 North European human samples. We compared HSMIA with established EIAs and focus reduction neutralization test (FRNT). <b>Results and discussion</b>: The Puumala hantavirus (PUUV) component in the HSMIA gave concordant results with a PUUV IgG EIA in 142 sera from Northern Sweden (of which 31 were EIA positive, 7 borderline and 104 EIA negative, sensitivity 30/31 = 97%, specificity 104/ 104 = 100%, 134/135 = 99% concordance), with another immunoassay in 40 PUUV IgG positive sera from Finland (36/40 = 90% sensitivity), and was concordant in 8 of 11 cases with PUUV and DOBV neutralization titers, respectively. Two major IgG reactivity patterns were found: (i) a PUUV-specific pattern covering phylogroup IV and its serogroups B and C; and (ii) a Dobrava virus (DOBV)-specific pattern, covering the serogroup A portion of phylogroup III. In addition, we found several minor patterns with reactivity to only one or two megapeptides indicating additional hantaviruses infecting humans in the Swedish and Finnish populations. <b>Conclusion</b>: The broadly reactive and rational HSMIA yielded results highly correlated with the established PUUV EIAs and the NT results. It is a sensitive and specific assay, which will be suited for efficient serosurveillance of hantaviruses in humans. Its use in animals should be further investigated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rönnberg</LastName><ForeName>Bengt</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-0229-093X</Identifier><AffiliationInfo><Affiliation>Section of Clinical Microbiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zoonosis Science Center, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Clinical Microbiology, Uppsala University Hospital, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vapalahti</LastName><ForeName>Olli</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Veterinary Biosciences and Virology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goeijenbier</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3165-8193</Identifier><AffiliationInfo><Affiliation>Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reusken</LastName><ForeName>Chantal</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gustafsson</LastName><ForeName>Åke</ForeName><Initials>Å</Initials><Identifier Source="ORCID">0000-0002-1472-1373</Identifier><AffiliationInfo><Affiliation>Laboratory of Clinical Microbiology, Uppsala University Hospital, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blomberg</LastName><ForeName>Jonas</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6492-2491</Identifier><AffiliationInfo><Affiliation>Section of Clinical Microbiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zoonosis Science Center, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lundkvist</LastName><ForeName>Åke</ForeName><Initials>Å</Initials><Identifier Source="ORCID">0000-0002-1472-1373</Identifier><AffiliationInfo><Affiliation>Section of Clinical Microbiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zoonosis Science Center, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Clinical Microbiology, Uppsala University Hospital, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Infect Ecol Epidemiol</MedlineTA><NlmUniqueID>101579795</NlmUniqueID><ISSNLinking>2000-8686</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Hantavirus</Keyword><Keyword MajorTopicYN="N">emerging or re-emerging diseases</Keyword><Keyword MajorTopicYN="N">laboratory surveillance</Keyword><Keyword MajorTopicYN="N">megapeptide</Keyword><Keyword MajorTopicYN="N">pathogen surveillance</Keyword><Keyword MajorTopicYN="N">suspension multiplex immunoassay</Keyword><Keyword MajorTopicYN="N">synthetic antigen</Keyword><Keyword MajorTopicYN="N">viral haemorrhagic fever</Keyword><Keyword MajorTopicYN="N">zoonoses</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>01</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>06</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28815001</ArticleId><ArticleId IdType="doi">10.1080/20008686.2017.1350086</ArticleId><ArticleId IdType="pii">1350086</ArticleId><ArticleId IdType="pmc">PMC5549826</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Med Virol. 1995 Aug;46(4):293-303</Citation><ArticleIdList><ArticleId IdType="pubmed">7595404</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2008 Oct 17;283(42):28297-304</Citation><ArticleIdList><ArticleId IdType="pubmed">18687679</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1996 Feb 15;216(2):397-406</Citation><ArticleIdList><ArticleId IdType="pubmed">8607269</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2015 Jul;96(Pt 7):1664-75</Citation><ArticleIdList><ArticleId IdType="pubmed">25787939</ArticleId></ArticleIdList></Reference><Reference><Citation>Protein Sci. 2006 Nov;15(11):2558-67</Citation><ArticleIdList><ArticleId IdType="pubmed">17001032</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2012 Aug;84(8):1298-303</Citation><ArticleIdList><ArticleId IdType="pubmed">22711359</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1999 Dec;180(6):2030-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10558964</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2013 Jul 04;18(27):null</Citation><ArticleIdList><ArticleId IdType="pubmed">23870077</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Virol. 2013 Sep;58(1):11-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23871164</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2001 Jan;82(Pt 1):129-38</Citation><ArticleIdList><ArticleId IdType="pubmed">11125166</ArticleId></ArticleIdList></Reference><Reference><Citation>Neth J Med. 2015 May;73(4):155-60</Citation><ArticleIdList><ArticleId IdType="pubmed">25968286</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol Methods. 1996 May;59(1-2):161-72</Citation><ArticleIdList><ArticleId IdType="pubmed">8793844</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1999 Sep 30;262(2):321-32</Citation><ArticleIdList><ArticleId IdType="pubmed">10502511</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Vaccine Immunol. 2012 Sep;19(9):1399-410</Citation><ArticleIdList><ArticleId IdType="pubmed">22787191</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Res. 2007 Feb;123(2):204-10</Citation><ArticleIdList><ArticleId IdType="pubmed">16997412</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Ecol Epidemiol. 2015 Feb 06;5:27215</Citation><ArticleIdList><ArticleId IdType="pubmed">25656468</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2012 Jan;86(2):972-81</Citation><ArticleIdList><ArticleId IdType="pubmed">22090114</ArticleId></ArticleIdList></Reference><Reference><Citation>Viral Immunol. 2002;15(1):177-92</Citation><ArticleIdList><ArticleId IdType="pubmed">11952140</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Virol. 2013 Feb;3(1):92-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23384818</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Anti Infect Ther. 2015 Aug;13(8):939-46</Citation><ArticleIdList><ArticleId IdType="pubmed">26091780</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2009 Aug;90(Pt 8):1923-31</Citation><ArticleIdList><ArticleId IdType="pubmed">19386780</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2015 Feb;87(2):263-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25521059</ArticleId></ArticleIdList></Reference><Reference><Citation>Swiss Med Wkly. 2014 Mar 20;144:w13937</Citation><ArticleIdList><ArticleId IdType="pubmed">24652684</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2014 Aug 14;19(32):null</Citation><ArticleIdList><ArticleId IdType="pubmed">25139076</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 2015 Jul;53(7):2292-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25972427</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 1997 Dec;35(12):3264-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9399531</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Virol. 1995;140(10):1763-73</Citation><ArticleIdList><ArticleId IdType="pubmed">7503677</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Emerg Med. 2013 Jun;31(6):978-82</Citation><ArticleIdList><ArticleId IdType="pubmed">23680331</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Genet Evol. 2015 Apr;31:158-60</Citation><ArticleIdList><ArticleId IdType="pubmed">25643870</ArticleId></ArticleIdList></Reference><Reference><Citation>FEMS Immunol Med Microbiol. 1998 Dec;22(4):309-15</Citation><ArticleIdList><ArticleId IdType="pubmed">9879922</ArticleId></ArticleIdList></Reference><Reference><Citation>Microarrays (Basel). 2016 Aug 10;5(3):null</Citation><ArticleIdList><ArticleId IdType="pubmed">27600087</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Res. 2014 Jul 17;187:55-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24440318</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Res. 2014 Jul 17;187:77-83</Citation><ArticleIdList><ArticleId IdType="pubmed">24487183</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2015 Jun;96(Pt 6):1238-47</Citation><ArticleIdList><ArticleId IdType="pubmed">25701819</ArticleId></ArticleIdList></Reference><Reference><Citation>Vector Borne Zoonotic Dis. 2011 Jun;11(6):697-700</Citation><ArticleIdList><ArticleId IdType="pubmed">21417923</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Virol. 2015 Feb;10:27-33</Citation><ArticleIdList><ArticleId IdType="pubmed">25562117</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiol Infect. 1999 Jun;122(3):447-53</Citation><ArticleIdList><ArticleId IdType="pubmed">10459649</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol Methods. 2006 Feb 20;309(1-2):200-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16406059</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Ecol Epidemiol. 2015 Jun 30;5:27698</Citation><ArticleIdList><ArticleId IdType="pubmed">26134289</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2011 Apr;63(4):894-903</Citation><ArticleIdList><ArticleId IdType="pubmed">21305505</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Nov 28;8(11):e81155</Citation><ArticleIdList><ArticleId IdType="pubmed">24312270</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2014 Aug 13;6(8):3097-109</Citation><ArticleIdList><ArticleId IdType="pubmed">25123683</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Med Virol. 2013 Jan;23(1):35-49</Citation><ArticleIdList><ArticleId IdType="pubmed">22761056</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Infect Dis. 2009;41(1):51-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18821445</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1991 Nov 30;338(8779):1353-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1682736</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2002 Jan;76(1):444-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11739712</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Ecol Epidemiol. 2016 Jun 01;6:31465</Citation><ArticleIdList><ArticleId IdType="pubmed">27258208</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Microbiol Infect Dis. 2004 Sep;23(9):711-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15322934</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W513-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18515843</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2001 Nov;65(3):605-13</Citation><ArticleIdList><ArticleId IdType="pubmed">11596100</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Rev Microbiol. 2014 Aug;40(3):261-72</Citation><ArticleIdList><ArticleId IdType="pubmed">23607444</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B96 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000B96 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:28815001
|texte= Serogrouping and seroepidemiology of North European hantaviruses using a novel broadly targeted synthetic nucleoprotein antigen array.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:28815001" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |